Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Summary as of May 17, 2018

May 17, 2018 - By Mary Markley

During Q4 2017 the big money sentiment decreased to 0.98. That’s change of 0.31, from 2017Q3’s 1.29. 20 investors sold all, 70 reduced holdings as Integra LifeSciences Holdings Corporation ratio turned negative. 65 grew stakes while 23 funds acquired stakes. Funds hold 70.22 million shares thus 2.95% more from 2017Q3’s 68.21 million shares.
Geode Cap Mgmt Ltd Company reported 563,397 shs stake. 123,198 are held by Sectoral Asset Management. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Koch holds 0.09% or 12,995 shs. Nuveen Asset Mgmt Lc owns 24,205 shs. D E Shaw Communication holds 0.01% or 135,051 shs. California Pub Employees Retirement Sys owns 128,561 shs. Principal Gp holds 0.02% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 484,347 shs. Fdx Advisors holds 0.01% or 7,622 shs. Cambridge Tru stated it has 19,669 shs. Virtu Financial Limited Co invested in 0.02% or 7,895 shs. Campbell Newman Asset Mgmt stated it has 0.06% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 92 were reported by Gemmer Asset Mgmt Ltd Limited Liability Company. Pnc Svcs Group invested in 62,111 shs. 7,526 were reported by Stone Ridge Asset Mgmt Lc.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

A total of 9 analysts rate Integra Lifesciences (NASDAQ:IART) as follows: 3 “Buy”, 6 “Hold” and 0 “Sell”. Тherefore 33% are bullish. (NASDAQ:IART) has 10 ratings reports on May 17, 2018 according to StockzIntelligence. On Thursday, April 26 JP Morgan maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating. JP Morgan has “Neutral” rating and $57 target. The company rating was maintained by Jefferies on Wednesday, April 25. On Wednesday, April 25 Cantor Fitzgerald maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) with “Hold” rating. On Thursday, March 29 the firm has “Buy” rating given by Oppenheimer. On Wednesday, April 11 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Neutral” rating given by JP Morgan. On Wednesday, February 28 the company was maintained by JMP Securities. On Tuesday, January 2 the firm earned “Market Perform” rating by Raymond James. The stock rating was downgraded by Bank of America to “Neutral” on Tuesday, January 2. Listed here are Integra LifeSciences Holdings Corporation (NASDAQ:IART) PTs and latest ratings.

25/04/2018 Broker: Jefferies Rating: Buy New Target: $70.0000 Maintain
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $55 New Target: $57 Maintain
25/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $52.0000 Maintain
11/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $50 New Target: $55 Maintain
05/04/2018 Broker: BTIG Research Rating: Neutral New Target: $56 Initiates Coverage On
29/03/2018 Broker: Oppenheimer Rating: Buy New Target: $58.0000 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $57 New Target: $60 Maintain
08/01/2018 Broker: Barclays Capital Rating: Hold New Target: $53.0
02/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $55 Downgrade
02/01/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade

IART is hitting $63.85 during the last trading session, after increased 1.04%.Integra LifeSciences Holdings Corporation is uptrending after having risen 29.35% since May 17, 2017. IART has 666,578 volume or 5.58% up from normal. IART outperformed by 17.80% the S&P 500.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The firm is worth $5.23 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.77.87 is the P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

A couple more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were announced by: Globenewswire.com which released on May 09, 2018 “Integra LifeSciences Prices Public Offering of Common Stock”, also Globenewswire.com on May 17, 2018 announced “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …”, the next Globenewswire.com is “Integra LifeSciences Reports First Quarter 2018 Financial Results” on April 25, 2018. Globenewswire.com has article titled “Integra LifeSciences Announces Proposed Public Offering of Common Stock”.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.